CELLECTISAct. Nom. Aktie [WKN DE: A0MKPR / ISIN: FR0010425595]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu CELLECTISAct. Nom.

02.01.18		Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT (Businesswire)
13.12.17		Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials (Businesswire)
04.12.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
04.12.17		Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development (Businesswire)
04.12.17		Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer (Businesswire)
20.11.17		Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy (Businesswire)
13.11.17		Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 (Businesswire)
08.11.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.11.17		FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN (Businesswire)
01.11.17		Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting (Businesswire)
01.11.17		Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting (Businesswire)
04.10.17		Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer (Businesswire)
04.10.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
07.09.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
05.09.17		Cellectis to Participate in Upcoming Investor Conferences (Businesswire)
05.09.17		Cellectis Reports Clinical Hold of UCART123 Studies (Businesswire)
17.08.17		Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center (Businesswire)
02.08.17		Cellectis: Monthly Information on Share Capital and Company Voting Rights (Businesswire)
02.08.17		Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 (Businesswire)
25.07.17		Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering (Businesswire)
24.07.17		Cellectis Granted Patent for CRISPR Use in T-Cells (Businesswire)
20.07.17		Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering (Businesswire)
10.07.17		Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million (Businesswire)
27.06.17		First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital (Businesswire)
23.06.17		Calyxt Files Registration Statement for Proposed Initial Public Offering (Businesswire)
28.05.17		Megatrends: Diesen 9 Aktien gehört die Zukunft! (finanzen.at)
23.01.17		Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
22.11.16		Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016 (Businesswire)
21.11.16		Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY (Businesswire)
15.11.16		Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123 (Businesswire)
07.11.16		Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting (Businesswire)
31.10.16		Cellectis Hosts World’s First Gene Edited Dinner in NYC (Businesswire)
04.10.16		Cellectis Announces the Issuance of U.S. Patent 9,458,439 Following U.S. Patent 8,921,332 Issued in December 2014 (Businesswire)
27.09.16		Cellectis Wins 2016 Most Innovative European Biotech SME Award for Healthcare (Businesswire)
08.09.16		Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results (Businesswire)
27.06.16		Cellectis Named 2016 Technology Pioneer by the World Economic Forum (Businesswire)
27.06.16		MIT Technology Review Names Cellectis on Annual List of 50 Smartest Companies for Second Consecutive Year (Businesswire)
20.06.16		Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) (Businesswire)
19.05.16		Cellectis S.A. Reports Results from Shareholders’ General Meeting Held on May 17, 2016 (Businesswire)
11.05.16		Cellectis Reports First Quarter 2016 Financial Results (Businesswire)
02.05.16		Cellectis to Present Data on Its Allogeneic CAR T-Cell Programs at the 19th American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
21.03.16		Cellectis Announces RetroNectin® Supply and License Agreement with Takara Bio Inc. (Businesswire)
16.03.16		Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies (Businesswire)
08.03.16		Cellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016 (Businesswire)
02.03.16		Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility (Businesswire)
19.01.16		Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies (Businesswire)
11.01.16		Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions (Businesswire)
07.01.16		Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team (Businesswire)
23.12.15		Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies (Businesswire)
21.12.15		Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 - 14, 2016 (Businesswire)

Zurück | 1 | 2 | 3 | 4 | Weiter

Newssuche

Meistgelesene Nachrichten

Amazon-Aktie verliert deutlich: Amazon mit Umsatzwachstum und Gewinnplus - enttäuschende Prognose

Porsche-Aktie mit Rekordtief: Trotz hoher Kosten aus Strategieschwenk hält Porsche an Dividende fest

ATX-Papier Raiffeisen-Aktie: So viel hätte eine Investition in Raiffeisen von vor 5 Jahren abgeworfen

Goldpreis: Ruhe vor dem nächsten Sturm?

Canopy Growth-Aktie tiefrot: Canopy Growth verzeichnet weniger Umsatz

US-Börsen schließen im Minus -- ATX geht schwach ins Wochenende -- DAX nach Rekordhoch letztlich tiefer -- Märkte in Fernost schließlich uneins - Nikkei schwach

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	09.02.2025 22:05
Kaufwert:	EUR
	Hinzufügen Speichern